Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudia Lanvers

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
European Journal of Drug Metabolism and Pharmacokinetics|February 17, 2021
Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing DataGudrun Würthwein, Claudia Lanvers-Kaminsky, Christian Siebel, et al.
Pharmacogenomics|April 1, 2015
Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicityClaudia Lanvers-Kaminsky, Jason A Sprowl, Ingrid Malath, et al.
The American Journal of Pathology|January 30, 2010
Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventionsGiuliano Ciarimboli, Dirk Deuster, Arne Knief, et al.
Antimicrobial Agents and Chemotherapy|November 16, 2011
Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipientsGudrun Würthwein, Charlotte Young, Claudia Lanvers-Kaminsky, et al.
Antimicrobial Agents and Chemotherapy|July 28, 2010
Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipientsAndreas H Groll, Gerda Silling, Charlotte Young, et al.
Therapeutic Drug Monitoring|December 7, 2017
Therapeutic Drug Monitoring of Asparaginase Activity-Method Comparison of MAAT and AHA Test Used in the International AIEOP-BFM ALL 2009 TrialClaudia Lanvers-Kaminsky, Andrea Rüffer, Gudrun Würthwein, et al.
BMC Pharmacology & Toxicology|May 30, 2020
Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedureChristian Siebel, Gudrun Würthwein, Claudia Lanvers-Kaminsky, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|December 20, 2002
Radiation-induced changes of telomerase activity in a human Ewing xenograft tumorAndreas Schuck, Christopher Poremba, Claudia Lanvers, et al.
Haematologica|December 10, 2020
Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemiaAlaeddin Khalil, Gudrun Würthwein, Jana Golitsch, et al.
Hemasphere|June 5, 2023
Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children With Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study ProtocolCarmelo Rizzari, Anja Möricke, Maria Grazia Valsecchi, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
European Journal of Drug Metabolism and Pharmacokinetics|February 17, 2021
Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing DataGudrun Würthwein, Claudia Lanvers-Kaminsky, Christian Siebel, et al.
Pharmacogenomics|April 1, 2015
Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicityClaudia Lanvers-Kaminsky, Jason A Sprowl, Ingrid Malath, et al.
The American Journal of Pathology|January 30, 2010
Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventionsGiuliano Ciarimboli, Dirk Deuster, Arne Knief, et al.
Antimicrobial Agents and Chemotherapy|November 16, 2011
Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipientsGudrun Würthwein, Charlotte Young, Claudia Lanvers-Kaminsky, et al.
Antimicrobial Agents and Chemotherapy|July 28, 2010
Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipientsAndreas H Groll, Gerda Silling, Charlotte Young, et al.
Therapeutic Drug Monitoring|December 7, 2017
Therapeutic Drug Monitoring of Asparaginase Activity-Method Comparison of MAAT and AHA Test Used in the International AIEOP-BFM ALL 2009 TrialClaudia Lanvers-Kaminsky, Andrea Rüffer, Gudrun Würthwein, et al.
BMC Pharmacology & Toxicology|May 30, 2020
Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedureChristian Siebel, Gudrun Würthwein, Claudia Lanvers-Kaminsky, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|December 20, 2002
Radiation-induced changes of telomerase activity in a human Ewing xenograft tumorAndreas Schuck, Christopher Poremba, Claudia Lanvers, et al.
Haematologica|December 10, 2020
Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemiaAlaeddin Khalil, Gudrun Würthwein, Jana Golitsch, et al.
Hemasphere|June 5, 2023
Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children With Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study ProtocolCarmelo Rizzari, Anja Möricke, Maria Grazia Valsecchi, et al.
Pageof 6